Analyst Insights

Topeka Reaffirms Hold On Vistaprint N.V. Following F4Q14 Report

In a research note released this morning, Topeka Capital analyst Victor Anthony reaffirmed a Hold rating on Vistaprint N.V.

Topeka Maintains Buy On Shutterfly Following Release Of 2Q14 Results

In reaction to Shutterfly’s (SFLY) 2Q14 results, yesterday, Topeka Capital analyst Victor Anthony maintained a Buy rating on SFLY with a $58 price target. …

Topeka Reaffirms Buy On Liberty Interactive Following Sale Of Floral And Gifting Business To FTD

In a research report published today, Topeka Capital analyst Victor Anthony reaffirmed a Buy rating on Liberty Interactive Inc. (LINTA) with a $34 …

IAC/InterActiveCorp: We Continue To Recommend Purchase Of The Shares, Says Topeka

In a research note released this morning, Topeka Capital analyst Victor Anthony reaffirmed a Buy rating on IAC/ InterActiveCorp. (IACI) but lowered his …

HC Wainwright Reiterates Buy On United Therapeutics Following 2Q14 Earnings

In a research report released yesterday, HC Wainwright analyst Andrew Fein reiterated a Buy rating on United Therapeutics Corp. (UTHR) and raised his price …

For Long-Term Investors We Would Recommend Buying Sarepta, Says Roth Capital

In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price …

Janney Capital Markets Reiterates Buy On Vertex Following 2Q14 Revenue Release

In a research report issued yesterday, Janney Capital Markets analyst Kimberly Lee reiterated a Buy rating on Vertex Pharmaceuticals Inc. (VRTX) and gave it a Fair Value Estimate …

William Blair Maintains Buy On Ultimate Software Group Following Solid Revenue And Earnings Report

In a research report issued yesterday, William Blair analyst Justin Furby reiterated coverage on The Ultimate Software Group, Inc. (ULTI) with a Buy rating.

William Blair Maintains Outperform On Sequenom Following 2Q14 Results

On Tuesday, July 29 Sequenom (SQNM) reported second quarter 2014 results that included revenue of $39.8 million, which was a bit shy of the consensus …

We Believe Regeneron Will Continue To Deliver A Strong Success Story, Says Roth Capital

Yesterday, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Regeneron Pharmaceuticals (REGN) and raised his …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts